Metabolic HealthHigher Obesity Drug Doses May Offer Smaller Gains and More Side Effects
Higher doses of obesity drugs generally produce greater average weight loss, but the extra benefit may shrink as side effects and treatment discontinuation increase. This critical narrative review examines those tradeoffs for incretin drugs and newer treatments that act on multiple hormone receptors. The authors argue that the best dose depends on the goal, whether weight loss, blood sugar control, heart benefits, tolerability, or maintenance. They also distinguish the prescribed dose from how much drug actually reaches the body. Continuing treatment after weight loss is supported by existing studies, but the lowest effective maintenance dose remains unknown. Adjusting doses according to individual response is a research proposal, not a proven dosing method. This abstract-only summary supports discussing treatment goals and side effects with a clinician rather than assuming more medication is always better.
